GenSight Biologics Announces the Filing of its 2020 Universal Registration Document

Annual General Meeting on April 29, 2021

GenSight Biologics successfully raises €30 million in an oversubscribed private placement with European and US institutional investors

GenSight Biologics launches a reserved offering of c. €25 million by means of an accelerated bookbuilding process

GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021

GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs

GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non Human Primates

GenSight Biologics Reports Cash Position as of December 31, 2020 and Provides Operational Update

GenSight Biologics Announces its 2021 Financial Calendar

GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®